The Center has protocols for the preclinical testing of drugs in support of New Drug Applications. The primary focus has been on new radiodiagnostic drugs,
particularly brain imaging agents. Examples of publications in this area are provided below.
Kostyniak, P.J., Brenner, J.S., MacCubbin, A.E., Nakeeb, S., Kasliwal, R., and Kung, H.F.: The toxicity and mutagenicity
of S-3-Iodo-N-(1-ethyl-2-pyrrolidinyl) methyl-2-hydroxy-6-methoxy benzamide (IBZM), a new NS D-2 dopamine receptor imaging agent. Drug and Chem. Toxicol., 11(4): 433-442 (1988).
Kostyniak, P.J., MacCubbin, A.E.,
Nakeeb, S.M., John, E.K., Green, M.A., Schopp, E.M. and Kung, H.F.: Acute Toxicity and Mutagenicity of the Copper Complex of Pyruvaldehyde-bis-(N-4-methylthiosemicarbazone), Cu-PTSM. J. Appl. Toxicol. 10:
(6), 417-421 (1990).